FDA rejects Acorda seizure drug Plumiaz; shares drop
This article was originally published in Scrip
Executive Summary
Shares of Acorda Therapeutics fell 11% on 2 May after the company revealed it had received a complete response letter (CRL) from the FDA for the firm's diazepam nasal spray drug Plumiaz as a treatment for patients with epilepsy who experience cluster seizures.